CagriReta Dual Injection Pen Kit — Retatrutide + Cagrilintide Dual Protocol
Our most advanced quad-pathway metabolic combination — pairing triple-agonist Retatrutide (40mg) with long-acting amylin analogue Cagrilintide (4mg) for complete GLP-1, GIP, Glucagon, and Amylin receptor coverage.
Analytical Specifications & HPLC Purity
- Batch ID: SYN-26CR-9902N (RP-HPLC Purity: 99.58%)
- CAS / Formula: 2381089-83-2 / 1415456-99-3 | C221H342N46O68 + C194H312N54O59S2 (4731.3 + 4409.0 g/mol)
- Format: 40mg + 4mg Dual Kit | 1 click = 0.1667 mg
- Storage: 2°C – 8°C (Refrigerated) | Half-life: ~6–8 days
Kit Contents
- 1x Pen 1: Retatrutide 40mg System (4 x 10mg Cartridges)
- 1x Pen 2: Cagrilintide 4mg Precision Pen
- 20x Ultra-Fine 31G 4mm Siliconized Micro-Needles
- 1x Executive Dual-Pen Presentation Case & Verification Seal
60-Unit Pen Titration & Click Schedule
| Weeks | Dose | Clicks | Phase |
|---|---|---|---|
| Weeks 1–4 | 2.0 mg Reta + 0.25 mg Cagri | 12u Reta / 4u Cagri | Quad-Pathway Onboarding |
| Weeks 5–8 | 4.0 mg Reta + 0.50 mg Cagri | 24u Reta / 8u Cagri | Metabolic & Amylin Synergy |
| Weeks 9–12 | 6.0 mg Reta + 1.00 mg Cagri | 36u Reta / 15u Cagri | Advanced Lipolytic Phase |
| Week 13+ | 8.0–10.0 mg Reta + 1.50 mg Cagri | 48–60u Reta / 23u Cagri | Peak Quad-Agonist Protocol |